Contributions
Abstract: P1162
Type: Poster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Alemtuzumab is very effective in decreasing the annualized relapse rate (ARR) in naïve patients or in patients treated previously with SC interferón beta-1a, but data on the efficacy in patients switching from fingolimod (FTY) is limited.
Goals: To analyze alemtuzumab efficacy in patients who switched from FTY comparing to those who switched from other disease modifiying therapies (DMT).
Methods: Retrospective review in patients from Virgen Macarena Hospital, Seville, Spain. Baseline, demographic, and MS characteristic data were collected. Comparison groups: switched from FTY (FTY group) or other DMTs (DMT group).
Results: 50 patients were treated with alemtuzumab; 25 switched from fingolimod and 25 from other DMTs including interferons beta, glatiramer acetate, dimethyl fumarate, and natalizumab. Mean age in FTY and DMT groups was 39.7 and 40.5 years, respectively. Median disease duration was 14.6 and 14.2 years, respectively. Mean follow-up from time of first alemtuzumab course was 11.9 and 13.3 months, respectively. Mean index progression was -0.15 in both groups (95% CI 0.98-0.5). Mean (SD) ARR before treatment was 1.6 (0.85) and after treatment 0.16 (0.47) (p< 0.0001), with no statistical difference between the two groups (0.16 FTY and 0.04 DMT, p>0.01). Mean (SD) EDSS pre-treatment was 4.4 (1.49) and 6 months later it was 3.5 (1.92) (p< 0.001), with no difference between groups. Mean FTY washout period was 6.9 weeks (4-12) prior to first alemtuzumab course. At this point, all of our patients had lymphocyte counts in the normal range (median 1.38 x 109/L). Three patients experienced rebound of disease activity within the first month after FTY discontinuation.
Conclusions: Alemtuzumab is a very effective drug, decreasing ARR and leading to a sustained improvement of disability in our patients. Efficacy was similar in patients who switched from fingolimod to patients who switched from other DMTs.
Disclosure:
Sara Eichau received speaker honoraria and consulting fees from Novartis, Biogen, Genzyme, Merck-Serono y Teva.
Abstract: P1162
Type: Poster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Alemtuzumab is very effective in decreasing the annualized relapse rate (ARR) in naïve patients or in patients treated previously with SC interferón beta-1a, but data on the efficacy in patients switching from fingolimod (FTY) is limited.
Goals: To analyze alemtuzumab efficacy in patients who switched from FTY comparing to those who switched from other disease modifiying therapies (DMT).
Methods: Retrospective review in patients from Virgen Macarena Hospital, Seville, Spain. Baseline, demographic, and MS characteristic data were collected. Comparison groups: switched from FTY (FTY group) or other DMTs (DMT group).
Results: 50 patients were treated with alemtuzumab; 25 switched from fingolimod and 25 from other DMTs including interferons beta, glatiramer acetate, dimethyl fumarate, and natalizumab. Mean age in FTY and DMT groups was 39.7 and 40.5 years, respectively. Median disease duration was 14.6 and 14.2 years, respectively. Mean follow-up from time of first alemtuzumab course was 11.9 and 13.3 months, respectively. Mean index progression was -0.15 in both groups (95% CI 0.98-0.5). Mean (SD) ARR before treatment was 1.6 (0.85) and after treatment 0.16 (0.47) (p< 0.0001), with no statistical difference between the two groups (0.16 FTY and 0.04 DMT, p>0.01). Mean (SD) EDSS pre-treatment was 4.4 (1.49) and 6 months later it was 3.5 (1.92) (p< 0.001), with no difference between groups. Mean FTY washout period was 6.9 weeks (4-12) prior to first alemtuzumab course. At this point, all of our patients had lymphocyte counts in the normal range (median 1.38 x 109/L). Three patients experienced rebound of disease activity within the first month after FTY discontinuation.
Conclusions: Alemtuzumab is a very effective drug, decreasing ARR and leading to a sustained improvement of disability in our patients. Efficacy was similar in patients who switched from fingolimod to patients who switched from other DMTs.
Disclosure:
Sara Eichau received speaker honoraria and consulting fees from Novartis, Biogen, Genzyme, Merck-Serono y Teva.